Knowing your patient’s hereditary cancer risk is critical when it comes to making treatment decisions. Blending both genetic test status and personal cancer family history, the MyRisk Hereditary Cancer Panel represents the next generation of hereditary cancer risk testing. MyRisk is here to help you determine the right treatment for your patients with a report including comprehensive results and a guideline-based Medical Management Tool.
3 out of 4 patients pay $0
Average turnaround time is 7-14 days
We make genetic testing simple for your patients and your practice
Commitment to providing broad patient access
MyRisk Hereditary Cancer Panel
Multi-gene panel determines hereditary cancer risk associated with 11 cancer sites:
MyRisk Management Tool (MMT)
The MyRisk test report provides recommendations for managing patients with both positive AND negative genetic results. Every report includes the MyRisk Genetic Result and a personalized MyRisk Medical Management Tool based on professional society guidelines.
In the past, family history screening has been too complex and time consuming. myGeneHistory is a simple patient friendly questionnaire that patients take before arriving or in your office. Patients input personal and family history into myGeneHistory. Once completed, the patient and you will be informed if they meet guidelines for genetic testing. Results from myGeneHistory are automatically saved into your MyriadPro account where you’ll be able to order Myriad genetics tests quickly and easily.
Learn about the benefits of myGeneHistory and how to implement it into your practice.
Myriad is the unquestioned industry leader in variant classification and reclassification. myVision™ is the most advanced program in the industry overseeing the classification and reclassification of uncertain variants and is part of Myriad’s commitment to patients and their families.
Variants Classified in 2016
Variants Re-classified in 2016
Amended Reports Issued in 2016
Myriad is dedicated, above all else, to improving patient care through pioneering research and the development of innovative molecular diagnostic tests. Since 1991, Myriad has invested more than a billion dollars to enhance the world’s collective scientific understanding of disease through collaborative research, outreach and education and to translate that knowledge into molecular and companion diagnostic tools that save and improve the lives of the patients we serve.
Scientific publications consisting of clinically meaningful information have been published in peer reviewed journals over the past 5 years
Invested in research over the past 5 years
Academic institutions have collaborated with Myriad to help advance medical and scientific knowledge and healthcare overall. You can view a list of these institutions here.
2022 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.